← Back to Search

Wilm's Tumor PO1 for Aniridia

N/A
Waitlist Available
Led By Louise C. Strong, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
1. Patients with familial and sporadic Wilm's tumor, genitourinary anomalies, Beckwith-Wiedemann hemihypertrophy and/or aniridia, and family members of patients.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 32 years (descriptive data collected using questionnaires)
Awards & highlights
No Placebo-Only Group

Summary

The goal of this clinical research study is to collect information and blood samples to try to learn why some people develop cancers and tumors, why some families have more cancers than others, and whether certain genes or regions of DNA (the genetic material of cells) affect a person's risk of getting cancer. This is an investigational study. Up to 1500 patients and family members will take part in this study. All will be enrolled at MD Anderson.

Eligible Conditions
  • Aniridia
  • Wilms Tumor

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~32 years (descriptive data collected using questionnaires)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 32 years (descriptive data collected using questionnaires) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Genetic Events Involved in Development of Wilms' tumor, Genitourinary Anomalies, Hemihypertrophy and Beckwith-Wiedemann, and/or Aniridia

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Wilm's Tumor PO1Experimental Treatment2 Interventions
Familial and Sporadic Wilm's tumor, genitourinary anomalies, Beckwith-Wiedemann hemihypertrophy and/or aniridia.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Questionnaire
2014
Completed Phase 2
~19970

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,055 Previous Clinical Trials
1,798,924 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,888 Previous Clinical Trials
41,020,863 Total Patients Enrolled
Louise C. Strong, MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
577 Total Patients Enrolled
~7 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top